FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969440081> ?p ?o ?g. }

• W2969440081 abstract "The ability of Plasmodium falciparum parasites to develop resistance to widely used anti-malarials threatens malaria control and elimination efforts. Regular drug efficacy monitoring is essential for ensuring effective treatment policies. In low transmission settings where therapeutic efficacy studies are often not feasible, routine surveillance for molecular markers associated with anti-malarial resistance provides an alternative for the early detection of emerging resistance. Such a longitudinal survey of changes in the prevalence of selected molecular markers of resistance was conducted in the malaria-endemic regions of Mpumalanga Province, South Africa, where malaria elimination at a district-level is being pursued. Molecular analyses to determine the prevalence of alleles associated with resistance to lumefantrine (mdr86N, crt76K and mdr1 copy number variation) and sulfadoxine–pyrimethamine (dhfr triple, dhps double, SP quintuple) were conducted between 2001 and 2018, while artemisinin resistance markers (kelch13 mutations) were assessed only in 2018. Parasite DNA was successfully amplified from 1667/2393 (70%) of malaria-positive rapid diagnostic tests routinely collected at primary health care facilities. No artemisinin resistance-associated kelch13 mutations nor amplification of the mdr1 gene copy number associated with lumefantrine resistance were observed. However, prevalence of both the mdr86N and crt76K alleles increased markedly over the study period, with all isolates collected in 2018 carrying these markers. SP quintuple mutation prevalence increased steadily from 14% in 2001 to 96% in 2018. Mixed alleles at any of the codons assessed were rare by 2018. No kelch13 mutations confirmed or suspected to be associated with artemisinin resistance were identified in 2018. Although parasites carrying the mdr86N and crt76K alleles associated with reduced lumefantrine susceptibility were strongly selected for over the study period, nearing fixation by 2018, the marker for lumefantrine resistance, namely increased mdr1 copy number, was not observed in this study. The increase in mdr86N and crt76K allele prevalence together with intense regional artemether–lumefantrine drug pressure, raises concern regarding the sustained artemether–lumefantrine efficacy. Regular, rigorous anti-malarial resistance marker surveillance across all three South African malaria-endemic provinces to inform case management is recommended." @default.
• W2969440081 created "2019-08-29" @default.
• W2969440081 creator A5026632577 @default.
• W2969440081 creator A5032900153 @default.
• W2969440081 creator A5046635231 @default.
• W2969440081 creator A5056514197 @default.
• W2969440081 creator A5064563319 @default.
• W2969440081 creator A5074824731 @default.
• W2969440081 creator A5083213248 @default.
• W2969440081 date "2019-08-22" @default.
• W2969440081 modified "2023-10-14" @default.
• W2969440081 title "Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001–2018)" @default.
• W2969440081 cites W1189868779 @default.
• W2969440081 cites W1963850122 @default.
• W2969440081 cites W1970665084 @default.
• W2969440081 cites W1984655801 @default.
• W2969440081 cites W1987034327 @default.
• W2969440081 cites W1995204372 @default.
• W2969440081 cites W1996647930 @default.
• W2969440081 cites W2001645156 @default.
• W2969440081 cites W2033885951 @default.
• W2969440081 cites W2036623541 @default.
• W2969440081 cites W2036678624 @default.
• W2969440081 cites W2064855181 @default.
• W2969440081 cites W2066434814 @default.
• W2969440081 cites W2079362200 @default.
• W2969440081 cites W2097263871 @default.
• W2969440081 cites W2102395543 @default.
• W2969440081 cites W2103439634 @default.
• W2969440081 cites W2107513184 @default.
• W2969440081 cites W2114566476 @default.
• W2969440081 cites W2119156545 @default.
• W2969440081 cites W2121065670 @default.
• W2969440081 cites W2124634096 @default.
• W2969440081 cites W2132831164 @default.
• W2969440081 cites W2136357433 @default.
• W2969440081 cites W2152672321 @default.
• W2969440081 cites W2154299250 @default.
• W2969440081 cites W2154934862 @default.
• W2969440081 cites W2160884305 @default.
• W2969440081 cites W2161311583 @default.
• W2969440081 cites W2163540657 @default.
• W2969440081 cites W2164272027 @default.
• W2969440081 cites W2165552432 @default.
• W2969440081 cites W2170637247 @default.
• W2969440081 cites W2171102256 @default.
• W2969440081 cites W2333050857 @default.
• W2969440081 cites W2585849544 @default.
• W2969440081 cites W2590767446 @default.
• W2969440081 cites W2752610535 @default.
• W2969440081 cites W2791105224 @default.
• W2969440081 cites W2802043998 @default.
• W2969440081 cites W2897102861 @default.
• W2969440081 cites W2900465495 @default.
• W2969440081 cites W2912798358 @default.
• W2969440081 cites W2954138883 @default.
• W2969440081 cites W4235101093 @default.
• W2969440081 doi "https://doi.org/10.1186/s12936-019-2911-y" @default.
• W2969440081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6704579" @default.
• W2969440081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31438951" @default.
• W2969440081 hasPublicationYear "2019" @default.
• W2969440081 type Work @default.
• W2969440081 sameAs 2969440081 @default.
• W2969440081 citedByCount "16" @default.
• W2969440081 countsByYear W29694400812020 @default.
• W2969440081 countsByYear W29694400812021 @default.
• W2969440081 countsByYear W29694400812022 @default.
• W2969440081 countsByYear W29694400812023 @default.
• W2969440081 crossrefType "journal-article" @default.
• W2969440081 hasAuthorship W2969440081A5026632577 @default.
• W2969440081 hasAuthorship W2969440081A5032900153 @default.
• W2969440081 hasAuthorship W2969440081A5046635231 @default.
• W2969440081 hasAuthorship W2969440081A5056514197 @default.
• W2969440081 hasAuthorship W2969440081A5064563319 @default.
• W2969440081 hasAuthorship W2969440081A5074824731 @default.
• W2969440081 hasAuthorship W2969440081A5083213248 @default.
• W2969440081 hasBestOaLocation W29694400811 @default.
• W2969440081 hasConcept C114851261 @default.
• W2969440081 hasConcept C159047783 @default.
• W2969440081 hasConcept C190612196 @default.
• W2969440081 hasConcept C203014093 @default.
• W2969440081 hasConcept C2776120307 @default.
• W2969440081 hasConcept C2777035104 @default.
• W2969440081 hasConcept C2778048844 @default.
• W2969440081 hasConcept C2778371730 @default.
• W2969440081 hasConcept C2778629330 @default.
• W2969440081 hasConcept C2780441369 @default.
• W2969440081 hasConcept C2780780316 @default.
• W2969440081 hasConcept C2780866276 @default.
• W2969440081 hasConcept C54355233 @default.
• W2969440081 hasConcept C71924100 @default.
• W2969440081 hasConcept C86803240 @default.
• W2969440081 hasConcept C90856448 @default.
• W2969440081 hasConceptScore W2969440081C114851261 @default.
• W2969440081 hasConceptScore W2969440081C159047783 @default.
• W2969440081 hasConceptScore W2969440081C190612196 @default.
• W2969440081 hasConceptScore W2969440081C203014093 @default.
• W2969440081 hasConceptScore W2969440081C2776120307 @default.
• W2969440081 hasConceptScore W2969440081C2777035104 @default.
• W2969440081 hasConceptScore W2969440081C2778048844 @default.

• next